Journal Articles

Perioperative pembrolizumab in locally advanced CSCC- A prospective phase 2 clinical trial

Spotlight 

In a phase 2 clinical trial for high-risk, resectable CSCC, Galloway, Das Neves, Amatore, et al. evaluated neoadjuvant treatment with two doses of pembrolizumab. Upon surgical resection, 56% of the 27 evaluable patients had a pathological complete response (PCR; no viable tumor remaining). While 81.5% patients continued on adjuvant pembrolizumab, 93.3% of those with PCR chose to forego adjuvant radiation, with no recurrences during a median follow-up of over 3 years. PCR was associated with post-treatment lymphoid aggregates of DCs, B cells, TCF1+CD8+ T cells, and HEVs. Non-response was associated with a TIME rich in PD-L1+ macrophages.

Contributed by Lauren Hitchings

In a phase 2 clinical trial for high-risk, resectable CSCC, Galloway, Das Neves, Amatore, et al. evaluated neoadjuvant treatment with two doses of pembrolizumab. Upon surgical resection, 56% of the 27 evaluable patients had a pathological complete response (PCR; no viable tumor remaining). While 81.5% patients continued on adjuvant pembrolizumab, 93.3% of those with PCR chose to forego adjuvant radiation, with no recurrences during a median follow-up of over 3 years. PCR was associated with post-treatment lymphoid aggregates of DCs, B cells, TCF1+CD8+ T cells, and HEVs. Non-response was associated with a TIME rich in PD-L1+ macrophages.

Contributed by Lauren Hitchings

ABSTRACT: Cutaneous squamous cell carcinoma (CSCC) is the second most common skin cancer and a leading cause of non-melanoma skin cancer mortality. We conducted a phase 2 trial (NCT04808999) evaluating neoadjuvant pembrolizumab (200 mg intravenous [i.v.] every 3 weeks for 2 cycles) followed by surgery and adjuvant pembrolizumab in patients with high-risk resectable CSCC. The primary endpoint was pathologic complete response (PCR) by immune-related pathologic response criteria. Thirty patients were enrolled, and 27 underwent protocol-defined surgery and were evaluable for response. PCR was achieved in 15 patients (55.6%; 95% confidence interval [CI], 35.3%–74.5%) and was associated with a trend toward reduced 3-year recurrence risk (Gray’s p = 0.07). Adjuvant radiotherapy was omitted in 93.3% of PCR cases. Multiplex immunofluorescence and transcriptional analyses identified B cell- and dendritic cell-enriched lymphoid aggregates as correlates of PCR, whereas non-responders exhibited PD-L1-enriched macrophage- and tumor-dominant microenvironments. These findings support biomarker-driven treatment de-escalation strategies.

Author Info: (1)- University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center, Pittsburgh, PA, USA (2)- Division of Malignant Hematology and Oncology, Department of Medicine, Universit

Author Info: (1)- University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center, Pittsburgh, PA, USA (2)- Division of Malignant Hematology and Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA (3)- Division of Dermatopathology, Department of Dermatology, University of Pittsburgh, Pittsburgh, PA, USA (4)- Department of Otolaryngology, University of Pittsburgh, Pittsburgh, PA, USA (5)- Department of Biostatistics, School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA (6)- Department of Pathology, University of Pittsburgh, Pittsburgh, PA, USA (7)- NSABP Foundation, Inc., Pittsburgh, PA, USA (8)- Department of Radiation Oncology, University of Pittsburgh, Pittsburgh, PA, USA (9)- Department of Otolaryngology and Head and Neck Surgery, NYU Grossman School of Medicine, New York, NY, USA (10)- Division of Surgical Oncology, Department of Surgery, University of Pittsburgh, Pittsburgh, PA, USA (11)- Department of Dermatology, University of Pittsburgh, Pittsburgh, PA, USA (12)- Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA (13)- Department of Electrical and Computer Engineering, Swanson School of Engineering, University of Pittsburgh, Pittsburgh, PA, USA (14)- Department of Pharmaceutical Sciences, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA (15)- Department of Immunology, University of Pittsburgh, Pittsburgh, PA, USA (16)- These authors contributed equally (17)- Senior author (18)- Lead contact

Relatlimab plus nivolumab versus nivolumab for advanced melanoma: 5-year survival and biomarker analyses of the phase 3 RELATIVITY-047 trial Spotlight 

In a 5-year follow-up (minimum 57.3 months) of the RELATIVITY-047 trial, which led to the approval of nivolumab (anti-PD-1) plus relatlimab (anti-Lag3) for patients with metastatic, unresectable melanoma, Long et al. noted long-term benefits in progression-free, overall, and melanoma-specific survival versus nivolumab alone. In a subset of patients with PD-L1 ≥1%, survival curves separated after 3 years, and while those with high Lag3+ CD8+ T cells showed worse outcomes with nivolumab alone, they experienced greater late or post-progression benefits from relatlimab, suggesting mitigation of Lag3+ T cell-mediated primary resistance.

Contributed by Lauren Hitchings

In a 5-year follow-up (minimum 57.3 months) of the RELATIVITY-047 trial, which led to the approval of nivolumab (anti-PD-1) plus relatlimab (anti-Lag3) for patients with metastatic, unresectable melanoma, Long et al. noted long-term benefits in progression-free, overall, and melanoma-specific survival versus nivolumab alone. In a subset of patients with PD-L1 ≥1%, survival curves separated after 3 years, and while those with high Lag3+ CD8+ T cells showed worse outcomes with nivolumab alone, they experienced greater late or post-progression benefits from relatlimab, suggesting mitigation of Lag3+ T cell-mediated primary resistance.

Contributed by Lauren Hitchings

ABSTRACT: Nivolumab plus relatlimab is approved for advanced melanoma based on the RELATIVITY-047 trial; however, long-term data are needed. Here we report data from RELATIVITY-047 with the longest follow-up at present. In this phase 2-3, double-blind trial, patients with metastatic/unresectable melanoma were randomized 1:1 to nivolumab 480 mg plus relatlimab 160 mg (n = 355) or nivolumab 480 mg (n = 359) intravenously every 4 weeks. The primary endpoint was progression-free survival (PFS) by blinded independent central review. Secondary endpoints were overall survival (OS), response and safety. Additional post hoc analyses, such as melanoma-specific survival (MSS) and exploratory biomarker analyses, are also reported. This analysis shows clear separation in survival curves with the largest absolute differences to date in PFS, OS and MSS. In this prespecified 5-year analysis, with a minimum follow-up of 57.3 months, nivolumab plus relatlimab demonstrated continued clinically significant benefit versus nivolumab for PFS (hazard ratio (HR) = 0.77; 95% confidence interval (CI): 0.65-0.92), OS (HR = 0.78; 95% CI: 0.64-0.95) and MSS (HR = 0.71; 95% CI: 0.57-0.88). The safety profile remained consistent with prior reports. Among biomarker-evaluable patients in the PD-L1 ≥1% subgroup, analyses revealed an association between worse outcomes with nivolumab and high peripheral or tumor LAG-3+ CD8 cell levels. The addition of relatlimab to nivolumab was associated with a lower prevalence of primary resistance than nivolumab alone. These data support the hypothesis that relatlimab can overcome LAG-3-mediated resistance to nivolumab and provide evidence for differential efficacy patterns observed across biomarker subgroups linked to primary versus acquired resistance states. ClinicalTrials.gov identifier: NCT03470922 .

Author Info: (1) Melanoma Institute Australia, The University of Sydney Royal North Shore and Mater Hospitals, Sydney, New South Wales, Australia. georgina.long@sydney.edu.au. (2) Bristol Myers

Author Info: (1) Melanoma Institute Australia, The University of Sydney Royal North Shore and Mater Hospitals, Sydney, New South Wales, Australia. georgina.long@sydney.edu.au. (2) Bristol Myers Squibb, Princeton, NJ, USA. (3) Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. (4) Department of Oncology, The Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, The Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA. (5) Department of Dermatology, University Hospital Essen, Essen, Germany. German Cancer Consortium, Campus Essen, Essen, Germany. National Center for Tumor Diseases (NCT-West), Campus Essen, Essen, Germany. Research Alliance Ruhr, Research Center One Health, University Duisburg-Essen, Campus Essen, Essen, Germany. (6) University of Naples Federico II, Naples, Italy. Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, Italy. (7) Department of Oncology, Instituto Oncol—gico Fundaci—n Arturo L—pez PŽrez, Santiago, Chile. Department of Oncology, Instituto Nacional del C‡ncer, Santiago, Chile. (8) Department of Oncology, FAICIC Clinical Research, Veracruz, Mexico. (9) Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sk_odowska-Curie National Research Institute of Oncology, Warsaw, Poland. (10) Department of Medicine, National and Kapodistrian University of Athens, Athens, Greece. (11) Department of Internal Medicine, Michigan Medicine, Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA. (12) Department of Internal Medicine, Michigan Medicine, Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA. (13) Department of Clinical Oncology, Hospital Nossa Senhora da Concei‹o, Porto Alegre, Brazil. (14) Department of Dermatology, Hospices Civils de Lyon, Cancer Research Center of Lyon, Pierre-BŽnite, France. (15) Department of Medical Oncology, Hospital Clinic de Barcelona and IDIBAPS, Barcelona, Spain. (16) Department of Dermatology and Skin Cancer, APHM, CHU Timone, Aix-Marseille University, Marseille, France. (17) Department of Oncology, iBiomed Clinical Research, Guadalajara, Mexico. (18) University of Siena, Siena, Italy. Department of Oncology, Center for Immuno-Oncology, University Hospital, Siena, Italy. (19) Bristol Myers Squibb, Princeton, NJ, USA. (20) Bristol Myers Squibb, Princeton, NJ, USA. (21) Bristol Myers Squibb, Princeton, NJ, USA. (22) Bristol Myers Squibb, Princeton, NJ, USA. (23) Bristol Myers Squibb, Princeton, NJ, USA. (24) Bristol Myers Squibb, Princeton, NJ, USA. (25) Bristol Myers Squibb, Boudry, Switzerland. (26) Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Lower airway microbiome transcriptional and metabolic activities influence responsiveness to immunotherapy in NSCLC

ABSTRACT: Immune checkpoint inhibitors (ICIs) have transformed the treatment of advanced non-small cell lung cancer (NSCLC), yet a large proportion of patients do not respond. The lung microbiome is a key modulator of antitumor immunity, however, the functional contribution of active microbial communities and their interaction with host transcriptional programs in shaping ICI outcomes remain poorly defined. Here, we prospectively analyzed bronchoalveolar lavage (BAL) samples from 71 NSCLC patients prior to ICI initiation. We profiled the microbiome and host transcriptome in the BAL to look for microbial and host signatures in the lower airways associated with treatment response. We found that enrichment of the lower airway microbiome with oral commensals was associated with disease progression and worse prognosis of patients treated with ICI. Metatranscriptomics-derived microbial clustering revealed distinct functional profiles. The microbial cluster enriched with oral commensals, which was only present among patients with poor response to ICI, had differential regulation of pathways involved in the metabolism of short-chain fatty acids, methane, and pyruvate. This cluster also correlated with host immune pathways including upregulation of interferon signaling, neutrophil degranulation, and mitophagy, all of which could contribute to the poor response to immunotherapy. In a preclinical murine model of lung cancer with dysbiosis, inoculating lung tumor-bearing mice with oral commensals increased intratumoral neutrophils and Th17 responses and impaired ICI efficacy. Our findings support the concept that microbial communities in the lower airways influence tumor-immune interactions via defined metabolic-immune axes.

Author Info: (1) NYU Langone Medical Center New York, New York United States. (2) New York University New York, New York United States. ROR: https://ror.org/0190ak572 (3) New York University Ne

Author Info: (1) NYU Langone Medical Center New York, New York United States. (2) New York University New York, New York United States. ROR: https://ror.org/0190ak572 (3) New York University New York, New York United States. ROR: https://ror.org/0190ak572 (4) New York University NY, NY United States. ROR: https://ror.org/0190ak572 (5) NYU Langone Medical Center New York, New York United States. (6) New York University New York, NY United States. ROR: https://ror.org/0190ak572 (7) National Institutes of Health Bethsada, MD United States. ROR: https://ror.org/01cwqze88 (8) New York University Grossman School of Medicine New York, NY United States. (9) New York University New York, New York United States. ROR: https://ror.org/0190ak572 (10) NYU Langone Medical Center New York, New York United States. (11) New York University New York, New York United States. ROR: https://ror.org/0190ak572 (12) NYU Langone Health New York, New York United States. ROR: https://ror.org/005dvqh91 (13) New York University New York, New York United States. ROR: https://ror.org/0190ak572 (14) New York University New York, New York United States. ROR: https://ror.org/0190ak572 (15) NYU Langone Health New York, NY United States. ROR: https://ror.org/005dvqh91 (16) NYU Langone Health New York, NY United States. ROR: https://ror.org/005dvqh91 (17) NYU Langone Medical Center New York, New York United States. (18) New York University New York, New York United States. ROR: https://ror.org/0190ak572 (19) NYU Langone Health New York, NY United States. ROR: https://ror.org/005dvqh91 (20) New York University Grossman School of Medicine New York, New York United States. (21) NYU Langone Health New York, NY United States. ROR: https://ror.org/005dvqh91 (22) New York University New York, New York United States. ROR: https://ror.org/0190ak572 (23) NYU Langone Medical Center New York, New York United States. (24) NYU Langone Medical Center New York, New York United States. (25) NYU Langone Medical Center New York, New York United States. (26) NYU Langone's Laura and Isaac Perlmutter Cancer Center New York, NY United States. ROR: https://ror.org/00sa8g751 (27) NYU Langone's Laura and Isaac Perlmutter Cancer Center New York, NY United States. ROR: https://ror.org/00sa8g751 (28) Gutz Analytics BOULDER, CO United States. (29) Gutz Analytics United States. (30) New York University Grossman School of Medicine New York, New York United States. (31) NYU Langone Health New York, NY United States. ROR: https://ror.org/005dvqh91 (32) Weill Cornell Medicine New York, NY United States. ROR: https://ror.org/02r109517 (33) NYU Langone Health New York, NY United States. ROR: https://ror.org/005dvqh91 (34) NYU Langone's Laura and Isaac Perlmutter Cancer Center New York, ny United States. ROR: https://ror.org/00sa8g751 (35) New York University New York City, NY United States. ROR: https://ror.org/0190ak572 (36) NYU Langone Medical Center New York, NY United States. (37) Simons Foundation. ROR: https://ror.org/01cmst727 (38) New York University New York, New York United States. ROR: https://ror.org/0190ak572 (39) National Institutes of Health Bethsada, MD United States. ROR: https://ror.org/01cwqze88 (40) NYU Langone Medical Center New York, New York United States.

T cell cross-priming by PD-L1+ type 1 conventional dendritic cells mediates the antitumor efficacy of a PD-L1×4-1BB bispecific antibody

Spotlight 

Using genetic deletion, Luri-Rey et al. showed that in mouse models, the therapeutic efficacy of a PD-L×4-1BB bispecific antibody required PD-L1 expression on cDC1s, but not tumor cells. TdLN removal prior to therapy impaired tumor regression. PD-L1×4-1BB therapy enhanced tumor-antigen cross-presentation through IL-12, 4-1BB costimulation, and cDC1 licensing by CD40L. Therapy boosted cDC1–T cell contacts, T cell activation transcriptional programs, and tumor antigen-specific CD8+ T cell proliferation. cDC1 and activated CD8+ T cell infiltration and adjacency were increased in treated tumors. Flt3L increased DC prevalence to promote efficacy.

Contributed by Paula Hochman

Using genetic deletion, Luri-Rey et al. showed that in mouse models, the therapeutic efficacy of a PD-L×4-1BB bispecific antibody required PD-L1 expression on cDC1s, but not tumor cells. TdLN removal prior to therapy impaired tumor regression. PD-L1×4-1BB therapy enhanced tumor-antigen cross-presentation through IL-12, 4-1BB costimulation, and cDC1 licensing by CD40L. Therapy boosted cDC1–T cell contacts, T cell activation transcriptional programs, and tumor antigen-specific CD8+ T cell proliferation. cDC1 and activated CD8+ T cell infiltration and adjacency were increased in treated tumors. Flt3L increased DC prevalence to promote efficacy.

Contributed by Paula Hochman

ABSTRACT: Bispecific antibodies that conditionally engage costimulatory receptors aim to enhance antitumor T cell immunity while limiting systemic toxicity. We investigated mechanisms underlying the clinical performance of a PD-L1_4-1BB bispecific antibody. Therapeutic efficacy of PD-L1_4-1BB was largely independent of PD-L1 expression on malignant cells but waned in Batf3(-/-) mice or upon depletion of type 1 conventional dendritic cells (cDC1s). cDC1-specific deletion of PD-L1 markedly limited tumor control. PD-L1_4-1BB enhanced proliferation of tumor-antigen-specific CD8(+) T cells through mechanisms dependent on cross-presentation, the presence of interleukin (IL)-12, 4-1BB costimulation, and CD40L-mediated cDC1 licensing. PD-L1_4-1BB increased cDC1-T cell contacts, which promoted transcriptional programs associated with T cell activation and proliferation. Treated tumors exhibited increased infiltration and spatial proximity of cDC1s and activated CD8(+) T cells. Accordingly, increasing dendritic-cell abundance via Flt3L further enhanced tumor control. Thus, cDC1-T cell interactions are central to PD-L1_4-1BB activity, with antigen cross-presentation, dendritic-cell licensing, and IL-12 and 4-1BB costimulation converging to promote antitumor immunity.

Author Info: (1) Program of Immunology and Immunotherapy, CIMA Universidad de Navarra, Pamplona, Spain; Navarra Institute for Health Research (IDISNA), Pamplona, Spain; Centro de Investigaci—n

Author Info: (1) Program of Immunology and Immunotherapy, CIMA Universidad de Navarra, Pamplona, Spain; Navarra Institute for Health Research (IDISNA), Pamplona, Spain; Centro de Investigaci—n BiomŽdica en Red de C‡ncer (CIBERONC), Madrid, Spain. (2) Program of Immunology and Immunotherapy, CIMA Universidad de Navarra, Pamplona, Spain. (3) Program of Immunology and Immunotherapy, CIMA Universidad de Navarra, Pamplona, Spain. (4) Program of Immunology and Immunotherapy, CIMA Universidad de Navarra, Pamplona, Spain. (5) Program of Immunology and Immunotherapy, CIMA Universidad de Navarra, Pamplona, Spain. (6) Program of Immunology and Immunotherapy, CIMA Universidad de Navarra, Pamplona, Spain; Navarra Institute for Health Research (IDISNA), Pamplona, Spain. (7) Program of Immunology and Immunotherapy, CIMA Universidad de Navarra, Pamplona, Spain. (8) Program of Immunology and Immunotherapy, CIMA Universidad de Navarra, Pamplona, Spain. (9) Program of Immunology and Immunotherapy, CIMA Universidad de Navarra, Pamplona, Spain. (10) Program of Immunology and Immunotherapy, CIMA Universidad de Navarra, Pamplona, Spain; Navarra Institute for Health Research (IDISNA), Pamplona, Spain. (11) Program of Immunology and Immunotherapy, CIMA Universidad de Navarra, Pamplona, Spain; Navarra Institute for Health Research (IDISNA), Pamplona, Spain. (12) Program of Immunology and Immunotherapy, CIMA Universidad de Navarra, Pamplona, Spain. (13) Program of Immunology and Immunotherapy, CIMA Universidad de Navarra, Pamplona, Spain. (14) Department of Immunology, Institute of Advanced Medicine, Wakayama Medical University, Wakayama, Japan. (15) Department of Pathology, Anatomy and Physiology, Schools of Medicine and Sciences, University of Navarra and Cl’nica Universidad de Navarra, Pamplona, Spain. (16) Department of Pathology, Anatomy and Physiology, Schools of Medicine and Sciences, University of Navarra and Cl’nica Universidad de Navarra, Pamplona, Spain. (17) Department of Pathology, Anatomy and Physiology, Schools of Medicine and Sciences, University of Navarra and Cl’nica Universidad de Navarra, Pamplona, Spain. (18) Program in Solid Tumors, CIMA Universidad de Navarra, Pamplona, Spain. (19) Immunobiology Laboratory, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain. (20) Immunobiology Laboratory, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain. (21) Genmab BV, Utrecht, the Netherlands. (22) Genmab BV, Utrecht, the Netherlands. (23) Program of Immunology and Immunotherapy, CIMA Universidad de Navarra, Pamplona, Spain; Navarra Institute for Health Research (IDISNA), Pamplona, Spain; Centro de Investigaci—n BiomŽdica en Red de C‡ncer (CIBERONC), Madrid, Spain. (24) Department of Pathology, Anatomy and Physiology, Schools of Medicine and Sciences, University of Navarra and Cl’nica Universidad de Navarra, Pamplona, Spain. (25) Genmab U.S. Inc., Princeton, NJ, USA. (26) Program of Immunology and Immunotherapy, CIMA Universidad de Navarra, Pamplona, Spain; Navarra Institute for Health Research (IDISNA), Pamplona, Spain; Centro de Investigaci—n BiomŽdica en Red de C‡ncer (CIBERONC), Madrid, Spain. Electronic address: ateijeiras@unav.es. (27) Program of Immunology and Immunotherapy, CIMA Universidad de Navarra, Pamplona, Spain; Navarra Institute for Health Research (IDISNA), Pamplona, Spain; Centro de Investigaci—n BiomŽdica en Red de C‡ncer (CIBERONC), Madrid, Spain; Nuffield Department of Medicine, University of Oxford, Oxford, UK; Departments of Immunology and Oncology, Cl’nica Universidad de Navarra, Pamplona, Spain. Electronic address: imelero@unav.es.

Lifestyle-induced regulatory T cell fragility primes adverse events after immune checkpoint blockade Spotlight 

Patra et al. fed mice a low-fiber, high-fat Western diet (inducing dysbiosis and outgrowth of Akkermansia) and treated them with anti-PD-1 to obtain the lifestyle-induced susceptibility to immune-related adverse events (irAEs) mouse model, LISA. LISA recapitulated the ICB toxicity profile affecting many patients, and was influenced by known demographic factors. Cytotoxic tissue-resident memory CD8+ T cells (TRM) and Tregs were increased in affected tissues. Tregs were fragile, less suppressive, and secreted IFNγ. Treg-specific disruption of IFNγ production or signaling and dietary reversal reduced irAE severity, but not antitumor efficacy. Treg fragility and cytotoxic TRM were also present in human irColitis.

Contributed by Ute Burkhardt

Patra et al. fed mice a low-fiber, high-fat Western diet (inducing dysbiosis and outgrowth of Akkermansia) and treated them with anti-PD-1 to obtain the lifestyle-induced susceptibility to immune-related adverse events (irAEs) mouse model, LISA. LISA recapitulated the ICB toxicity profile affecting many patients, and was influenced by known demographic factors. Cytotoxic tissue-resident memory CD8+ T cells (TRM) and Tregs were increased in affected tissues. Tregs were fragile, less suppressive, and secreted IFNγ. Treg-specific disruption of IFNγ production or signaling and dietary reversal reduced irAE severity, but not antitumor efficacy. Treg fragility and cytotoxic TRM were also present in human irColitis.

Contributed by Ute Burkhardt

ABSTRACT: Immune checkpoint blockade has transformed cancer therapy, but immune-related adverse events (irAEs) remain a major, sometimes fatal, limitation, and the lack of robust preclinical models has hindered mechanistic insight. We present the lifestyle-induced susceptibility to irAEs (LISA) model, in which diet-driven metabolic and microbial alterations recreate human-like susceptibility to anti-PD-1 toxicity. LISA recapitulates multi-organ irAEs with immune infiltration and cytokine production, severity depending on sex, age, treatment modality, and immunotherapy response. Mechanistically, dysbiosis marked by Akkermansia muciniphila enrichment accompanies aberrant immune activation, driving regulatory T cell (Treg) fragility and CD8+ cytotoxic effector populations, both observed in patients with irColitis. Dietary reversal, metabolite supplementation, and blocking interferon (IFN)-γ production or signaling in Tregs restored Treg stability and resolved inflammation. Human-to-mouse fecal microbiome transfer interacts with recipient diet to shape susceptibility. Together, these findings identify dietary, microbial, and immune drivers of irAEs, which can be leveraged to improve immunotherapy responses while minimizing toxicity.

Author Info: (1) UPMC Hillman Cancer Center, Pittsburgh, PA 15206, USA; Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15206, USA; Tumor Microenvironment

Author Info: (1) UPMC Hillman Cancer Center, Pittsburgh, PA 15206, USA; Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15206, USA; Tumor Microenvironment Center, UPMC Hillman Cancer Center, Pittsburgh, PA 15206, USA. (2) UPMC Hillman Cancer Center, Pittsburgh, PA 15206, USA; Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15206, USA; Tumor Microenvironment Center, UPMC Hillman Cancer Center, Pittsburgh, PA 15206, USA; Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA. (3) UPMC Hillman Cancer Center, Pittsburgh, PA 15206, USA; Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15206, USA; Tumor Microenvironment Center, UPMC Hillman Cancer Center, Pittsburgh, PA 15206, USA; Program in Microbiology and Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. (4) Division of Laboratory Animal Resources, UPMC Hillman Cancer Center, Pittsburgh, PA 15213, USA. (5) UPMC Hillman Cancer Center, Pittsburgh, PA 15206, USA; Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15206, USA; Tumor Microenvironment Center, UPMC Hillman Cancer Center, Pittsburgh, PA 15206, USA; Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA. (6) UPMC Hillman Cancer Center, Pittsburgh, PA 15206, USA; Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15206, USA; Tumor Microenvironment Center, UPMC Hillman Cancer Center, Pittsburgh, PA 15206, USA. (7) UPMC Hillman Cancer Center, Pittsburgh, PA 15206, USA; Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15206, USA; Tumor Microenvironment Center, UPMC Hillman Cancer Center, Pittsburgh, PA 15206, USA; Program in Microbiology and Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. (8) UPMC Hillman Cancer Center, Pittsburgh, PA 15206, USA; Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15206, USA; Tumor Microenvironment Center, UPMC Hillman Cancer Center, Pittsburgh, PA 15206, USA. (9) UPMC Hillman Cancer Center, Pittsburgh, PA 15206, USA. (10) UPMC Hillman Cancer Center, Pittsburgh, PA 15206, USA; Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15206, USA; Tumor Microenvironment Center, UPMC Hillman Cancer Center, Pittsburgh, PA 15206, USA. (11) Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA; Health Sciences Mass Spectrometry Core, University of Pittsburgh, Pittsburgh, PA 15213, USA. (12) UPMC Hillman Cancer Center, Pittsburgh, PA 15206, USA; Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15206, USA; Tumor Microenvironment Center, UPMC Hillman Cancer Center, Pittsburgh, PA 15206, USA; Cellular and Molecular Pathology Program, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. (13) Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA; Health Sciences Mass Spectrometry Core, University of Pittsburgh, Pittsburgh, PA 15213, USA. (14) UPMC Hillman Cancer Center, Pittsburgh, PA 15206, USA; Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15206, USA; Tumor Microenvironment Center, UPMC Hillman Cancer Center, Pittsburgh, PA 15206, USA. (15) UPMC Hillman Cancer Center, Pittsburgh, PA 15206, USA. (16) UPMC Hillman Cancer Center, Pittsburgh, PA 15206, USA; Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15206, USA; Tumor Microenvironment Center, UPMC Hillman Cancer Center, Pittsburgh, PA 15206, USA; Center for Systems Immunology, Department of Immunology, University of Pittsburgh, Pittsburgh, PA 15206, USA. (17) UPMC Hillman Cancer Center, Pittsburgh, PA 15206, USA; Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15206, USA; Tumor Microenvironment Center, UPMC Hillman Cancer Center, Pittsburgh, PA 15206, USA. (18) UPMC Hillman Cancer Center, Pittsburgh, PA 15206, USA; Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15206, USA; Tumor Microenvironment Center, UPMC Hillman Cancer Center, Pittsburgh, PA 15206, USA. Electronic address: overacre@pitt.edu.

Five-year survival with neoadjuvant therapy in melanoma: updated pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC) Featured  

Long et al. performed a pooled analysis of long-term efficacy of neoadjuvant ICB and targeted therapies in stage IIIB-D melanoma. Pathological response was higher for ICB than for BRAF/MEKis, and higher for combination ICB than anti-PD-1 alone. Pathological response was associated with event-free, recurrence-free, and overall survival. Patients who had a pathological response to neoadjuvant ICB did not benefit from adjuvant ICB.

Long et al. performed a pooled analysis of long-term efficacy of neoadjuvant ICB and targeted therapies in stage IIIB-D melanoma. Pathological response was higher for ICB than for BRAF/MEKis, and higher for combination ICB than anti-PD-1 alone. Pathological response was associated with event-free, recurrence-free, and overall survival. Patients who had a pathological response to neoadjuvant ICB did not benefit from adjuvant ICB.

ABSTRACT: Neoadjuvant immune checkpoint inhibitors (ICIs) are standard of care for resectable stage IIIB-D melanoma, but knowledge gaps remain regarding optimal treatment type, long-term survival, postsurgical management and clinical, histopathological or molecular subgroups. We analyzed 1,038 patients treated with neoadjuvant ICIs (n = 735), BRAF and MEK inhibitors (BRAF/MEKis; n = 119) or ICI plus any targeted therapy (ICI + TT; n = 184) from 26 international sites in both trial (755, 72.7%) and nontrial (283, 27.3%) settings. ICI regimens included anti-programmed cell death protein 1 (PD-1) alone (PD-1 alone; n = 242) and anti-PD-1 plus other immuno-oncology agent(s) (PD-1 + IO; n = 489). Outcomes included major pathological response (MPR), recurrence-free survival (RFS) and overall survival (OS). An MPR was achieved in 57.8% of patients with ICIs, 51.4% with BRAF/MEKis and 44.6% with ICI + TT. PD-1 + IO elicited higher MPR rates than PD-1 alone (61.4% versus 49.5%). The 5-year RFS rate was 61.0% with PD-1 alone, 73.9% with PD-1 + IO, 37.4% with BRAF/MEKis and 76.4% with ICI + TT; the 5-year OS rates were 83.3%, 87.5%, 69.8% and 83.9%, respectively. ICI-treated patients with MPR had 5-year OS rates of 98.8% with PD-1 alone and 97.9% with PD-1 + IO and gained no benefit from continuing ICIs into the adjuvant setting. Neoadjuvant ICIs were active in BRAF-mutant melanoma (MPR, 46.3%), acral melanoma (38.1%), in-transit metastases (66.7%) and oligometastases (41.2%), although subgroup sizes and relative effectiveness varied. Survival outcomes were excellent with neoadjuvant ICIs, particularly in patients achieving MPR, but poor with BRAF/MEKis and mixed with ICI + TT. Predictive biomarker-driven trials, effective adjuvant strategies and subgroup-specific research are needed for nonresponders.

Author Info: (1) Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia. georgina.long@sydney.edu.au. Faculty of Health and Medicine, The University of Sydne

Author Info: (1) Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia. georgina.long@sydney.edu.au. Faculty of Health and Medicine, The University of Sydney, Sydney, New South Wales, Australia. georgina.long@sydney.edu.au. Charles Perkins Centre, The University of Sydney, Sydney, New South Wales, Australia. georgina.long@sydney.edu.au. Royal North Shore and Mater Hospitals, Sydney, New South Wales, Australia. georgina.long@sydney.edu.au. (2) Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia. Charles Perkins Centre, The University of Sydney, Sydney, New South Wales, Australia. Champalimaud Foundation, Lisbon, Portugal. (3) Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia. Charles Perkins Centre, The University of Sydney, Sydney, New South Wales, Australia. (4) Tygat Institute for Intestinal and Liver Research, Amsterdam UMC, Amsterdam, The Netherlands. (5) Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia. Charles Perkins Centre, The University of Sydney, Sydney, New South Wales, Australia. (6) Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia. Fiona Stanley Hospital, University of Western Australia, Perth, Western Australia, Australia. (7) Universitˆ degli Studi di Napoli 'Federico II', Naples, Italy. Istituto Nazionale Tumori IRCCS Fondazione 'G. Pascale', Naples, Italy. (8) University of Texas MD Anderson Cancer Center, Houston, TX, USA. (9) Mayo Clinic Comprehensive Cancer Center, Rochester, MN, USA. (10) Gustave Roussy, DŽpartement de MŽdecine Oncologique, UniversitŽ Paris-Saclay, Villejuif, France. (11) LMU University Hospital, Munich, Germany. (12) Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. (13) Centro de Referncia em Tumores Cut‰neos, AC Camargo Cancer Center, S‹o Paulo, Brazil. (14) Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. (15) H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA. (16) FSBI 'N. N. Blokhin National Medical Research Center of Oncology' of the Ministry of Health of the Russian Federation, Moscow, Russian Federation. (17) University of TŸbingen, TŸbingen, Germany. (18) UniversitŽ Paris Cite, AP-HP Dermato-oncology and CIC, Cancer Institute APHP.nord Paris citŽ, INSERM U1342-Equipe-CNRS EMR8000, Saint Louis Hospital, Paris, France. (19) Vanderbilt University Medical Center, Nashville, TN, USA. (20) Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland. (21) Vall d'Hebr—n Hospital and Vall d'Hebr—n Institute of Oncology (VHIO), Barcelona, Spain. (22) The Angeles Clinic and Research Institute, Los Angeles, CA, USA. (23) Istituto Nazionale Tumori IRCCS Fondazione 'G. Pascale', Naples, Italy. (24) Istituto Nazionale Tumori IRCCS Fondazione 'G. Pascale', Naples, Italy. (25) Mayo Clinic Comprehensive Cancer Center, Rochester, MN, USA. (26) Gustave Roussy, DŽpartement de MŽdecine Oncologique, UniversitŽ Paris-Saclay, Villejuif, France. (27) Gustave Roussy, DŽpartement de MŽdecine Oncologique, UniversitŽ Paris-Saclay, Villejuif, France. (28) LMU University Hospital, Munich, Germany. (29) Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. (30) H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA. (31) FSBI 'N. N. Blokhin National Medical Research Center of Oncology' of the Ministry of Health of the Russian Federation, Moscow, Russian Federation. (32) University of TŸbingen, TŸbingen, Germany. (33) Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia. Westmead and Blacktown Hospitals, Sydney, New South Wales, Australia. (34) University Medical Center Groningen, Groningen, The Netherlands. (35) Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA. (36) European Institute of Oncology, IRCCS Milan, Milan, Italy. (37) Leiden University Medical Center, Leiden, The Netherlands. (38) Erasmus Medical Center, Rotterdam, The Netherlands. (39) University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands. (40) UniversitŽ Paris Cite, AP-HP Dermato-oncology and CIC, Cancer Institute APHP.nord Paris citŽ, INSERM U1342-Equipe-CNRS EMR8000, Saint Louis Hospital, Paris, France. (41) Vanderbilt University Medical Center, Nashville, TN, USA. (42) Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland. (43) The Angeles Clinic and Research Institute, Los Angeles, CA, USA. (44) Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA. (45) Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA. (46) Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia. Royal Prince Alfred Hospital, Sydney, New South Wales, Australia. (47) University of Texas MD Anderson Cancer Center, Houston, TX, USA. (48) University of Texas MD Anderson Cancer Center, Houston, TX, USA. (49) University of California San Francisco, San Francisco, CA, USA. (50) Netherlands Cancer Institute, Amsterdam, The Netherlands. (51) Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia. Royal Prince Alfred Hospital, Sydney, New South Wales, Australia. NSW Health Pathology, Sydney, New South Wales, Australia. (52) Leiden University Medical Center, Leiden, The Netherlands. University Clinic Regensburg, Regensburg, Germany. European Institute of Oncology, Milan, Italy. (53) Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia. Charles Perkins Centre, The University of Sydney, Sydney, New South Wales, Australia. Royal North Shore and Mater Hospitals, Sydney, New South Wales, Australia.

Rejuvenating endogenous antitumor immunity via a chimeric receptor-engineered oncolytic virus targeting tumor-associated macrophages Spotlight 

Lin et al. engineered an oncolytic herpesvirus (oHSV) with a PD-L1 nanobody attached to gD on the viral envelope surface (gDαPD- L1), targeting the virus to both tumors and TAMs expressing PD-L1. In addition to its oncolytic activity, this CAR-oHSV also resulted in the presentation of anti-PD-L1 CARs on infected cells, blocking PD-L1 in cis. In TAMs, CAR-oHSV killed a subset of TAMs, while remaining TAMs were reprogrammed via STING activation towards a CXCL9+ antigen-presenting phenotype that supported CD8+ T cell-mediated antitumor immunity. CAR-oHSV was well tolerated and showed synergy with checkpoint blockade and adoptive cell therapy.

Contributed by Lauren Hitchings

Lin et al. engineered an oncolytic herpesvirus (oHSV) with a PD-L1 nanobody attached to gD on the viral envelope surface (gDαPD- L1), targeting the virus to both tumors and TAMs expressing PD-L1. In addition to its oncolytic activity, this CAR-oHSV also resulted in the presentation of anti-PD-L1 CARs on infected cells, blocking PD-L1 in cis. In TAMs, CAR-oHSV killed a subset of TAMs, while remaining TAMs were reprogrammed via STING activation towards a CXCL9+ antigen-presenting phenotype that supported CD8+ T cell-mediated antitumor immunity. CAR-oHSV was well tolerated and showed synergy with checkpoint blockade and adoptive cell therapy.

Contributed by Lauren Hitchings

ABSTRACT: Immunosuppressive tumor-associated macrophages (TAMs) create a barrier to effective antitumor immunity and promote therapeutic resistance. Reeducating TAMs to enhance their antitumor capabilities through phenotypic remodeling remains challenging. Here, we report a modular oncolytic herpesvirus platform, engineered with a PD-L1-specific chimeric receptor integrated into the viral envelope protein (CAR-oHSV). This design endows the virus with dual tropism, enabling it to target both tumor cells and TAMs within the tumor microenvironment. In virus-resistant tumor models, CAR-oHSV preferentially targets PD-L1(+) TAMs and triggers a STING-dependent reprogramming into a CXCL9(+) phenotype, enhancing their tumor antigen cross-presentation capability and inducing an endogenous antitumor T cell response. Furthermore, this platform can synergize with adoptive T cell therapy and immune checkpoint blockade therapy to overcome immunotherapy resistance. Collectively, our findings define a precision-oncolytic platform that dismantles TAM-mediated immunosuppression while amplifying adaptive immunity, offering a promising translational avenue for cancer immunotherapy.

Author Info: (1) State Key Laboratory of Vaccines for Infectious Diseases, Department of Laboratory Medicine, School of Public Health, Xiamen University, Xiamen, 361102, China. National Institu

Author Info: (1) State Key Laboratory of Vaccines for Infectious Diseases, Department of Laboratory Medicine, School of Public Health, Xiamen University, Xiamen, 361102, China. National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Xiang An Biomedicine Laboratory, Xiamen University, Xiamen, 361102, China. (2) State Key Laboratory of Vaccines for Infectious Diseases, Department of Laboratory Medicine, School of Public Health, Xiamen University, Xiamen, 361102, China. National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Xiang An Biomedicine Laboratory, Xiamen University, Xiamen, 361102, China. (3) State Key Laboratory of Vaccines for Infectious Diseases, Department of Laboratory Medicine, School of Public Health, Xiamen University, Xiamen, 361102, China. National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Xiang An Biomedicine Laboratory, Xiamen University, Xiamen, 361102, China. (4) State Key Laboratory of Vaccines for Infectious Diseases, Department of Laboratory Medicine, School of Public Health, Xiamen University, Xiamen, 361102, China. National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Xiang An Biomedicine Laboratory, Xiamen University, Xiamen, 361102, China. (5) State Key Laboratory of Vaccines for Infectious Diseases, Department of Laboratory Medicine, School of Public Health, Xiamen University, Xiamen, 361102, China. National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Xiang An Biomedicine Laboratory, Xiamen University, Xiamen, 361102, China. (6) State Key Laboratory of Vaccines for Infectious Diseases, Department of Laboratory Medicine, School of Public Health, Xiamen University, Xiamen, 361102, China. National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Xiang An Biomedicine Laboratory, Xiamen University, Xiamen, 361102, China. (7) State Key Laboratory of Vaccines for Infectious Diseases, Department of Laboratory Medicine, School of Public Health, Xiamen University, Xiamen, 361102, China. National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Xiang An Biomedicine Laboratory, Xiamen University, Xiamen, 361102, China. (8) State Key Laboratory of Vaccines for Infectious Diseases, Department of Laboratory Medicine, School of Public Health, Xiamen University, Xiamen, 361102, China. National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Xiang An Biomedicine Laboratory, Xiamen University, Xiamen, 361102, China. (9) State Key Laboratory of Vaccines for Infectious Diseases, Department of Laboratory Medicine, School of Public Health, Xiamen University, Xiamen, 361102, China. National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Xiang An Biomedicine Laboratory, Xiamen University, Xiamen, 361102, China. (10) State Key Laboratory of Vaccines for Infectious Diseases, Department of Laboratory Medicine, School of Public Health, Xiamen University, Xiamen, 361102, China. National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Xiang An Biomedicine Laboratory, Xiamen University, Xiamen, 361102, China. (11) State Key Laboratory of Vaccines for Infectious Diseases, Department of Laboratory Medicine, School of Public Health, Xiamen University, Xiamen, 361102, China. National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Xiang An Biomedicine Laboratory, Xiamen University, Xiamen, 361102, China. (12) State Key Laboratory of Vaccines for Infectious Diseases, Department of Laboratory Medicine, School of Public Health, Xiamen University, Xiamen, 361102, China. National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Xiang An Biomedicine Laboratory, Xiamen University, Xiamen, 361102, China. (13) State Key Laboratory of Vaccines for Infectious Diseases, Department of Laboratory Medicine, School of Public Health, Xiamen University, Xiamen, 361102, China. National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Xiang An Biomedicine Laboratory, Xiamen University, Xiamen, 361102, China. (14) State Key Laboratory of Vaccines for Infectious Diseases, Department of Laboratory Medicine, School of Public Health, Xiamen University, Xiamen, 361102, China. National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Xiang An Biomedicine Laboratory, Xiamen University, Xiamen, 361102, China. School of Life Sciences, Xiamen University, Xiamen, 361102, China. (15) State Key Laboratory of Vaccines for Infectious Diseases, Department of Laboratory Medicine, School of Public Health, Xiamen University, Xiamen, 361102, China. National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Xiang An Biomedicine Laboratory, Xiamen University, Xiamen, 361102, China.

Lower airway microbiome effects on responsiveness to immunotherapy in NSCLC

Spotlight 

To investigate the contribution of the lower airway microbiome to ICB responsiveness, Darawshy et al. analyzed BAL samples from 71 NSCLC patients prior to ICB treatment and compared functional microbial and host signatures between responders and non-responders. Multi-omic analyses of BAL revealed that enriched oral commensals correlated with poor ICB response, NSCLC progression, and worse prognosis, as well as upregulation of host interferon signaling, neutrophil degranulation and mitophagy. In a lung tumor model, inoculating oral commensals increased intratumoral neutrophils and Th17 responses, and impaired ICB efficacy.

Contributed by Katherine Turner

To investigate the contribution of the lower airway microbiome to ICB responsiveness, Darawshy et al. analyzed BAL samples from 71 NSCLC patients prior to ICB treatment and compared functional microbial and host signatures between responders and non-responders. Multi-omic analyses of BAL revealed that enriched oral commensals correlated with poor ICB response, NSCLC progression, and worse prognosis, as well as upregulation of host interferon signaling, neutrophil degranulation and mitophagy. In a lung tumor model, inoculating oral commensals increased intratumoral neutrophils and Th17 responses, and impaired ICB efficacy.

Contributed by Katherine Turner

ABSTRACT: Immune checkpoint inhibitors (ICIs) have transformed the treatment of advanced non-small cell lung cancer (NSCLC), yet a large proportion of patients do not respond. The lung microbiome is a key modulator of antitumor immunity, however, the functional contribution of active microbial communities and their interaction with host transcriptional programs in shaping ICI outcomes remain poorly defined. Here, we prospectively analyzed bronchoalveolar lavage (BAL) samples from 71 NSCLC patients prior to ICI initiation. We profiled the microbiome and host transcriptome in the BAL to identify microbial and host signatures in the lower airways associated with treatment response. Our data indicate that enrichment of the lower airway microbiome with oral commensals was commonly associated with disease progression and worse prognosis of patients treated with ICI. Metatranscriptomics-derived microbial clustering revealed distinct functional profiles. The microbial cluster enriched with oral commensals, which was only present among patients with poor response to ICI, had differential regulation of pathways involved in the metabolism of short- chain fatty acid, methane and pyruvate. This cluster also correlated with host immune pathways including upregulation of interferon signaling, neutrophil degranulation, and mitophagy which could contribute to the poor response to immunotherapy. A preclinical murine model of lung cancer with dysbiosis was used to examine the nature of the association further. Inoculating lung tumor-bearing mice with oral commensals increased intratumoral neutrophils and Th17 responses and impaired ICI efficacy. Our findings support the concept that microbial communities in the lower airways appear to influence tumor–immune interactions via defined metabolic– immune axes.

Author Info: (1) Division of Pulmonary and Critical Care Medicine, New York University Grossman School of Medicine, NYU Langone Health, New York, NY, USA (2) The Institute of Pulmonary Medicine

Author Info: (1) Division of Pulmonary and Critical Care Medicine, New York University Grossman School of Medicine, NYU Langone Health, New York, NY, USA (2) The Institute of Pulmonary Medicine, Hadassah Medical Center, Jerusalem, Israel (3) Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel (4) Department of Medicine, New York University Grossman School of Medicine, NYU Langone Health, New York, NY, USA (5) Division of Pulmonary and Critical Care Medicine, VA New York Harbor Healthcare System, New York, NY, USA (6) Center for Genomics and Systems Biology, New York University, New York, New York, USA (7) Department of Population Health, New York University School of Medicine, NYU Langone Health, New York, NY, USA (8) Systems Genomics Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA (9) Department of Radiology, New York University Grossman School of Medicine, NYU Langone Health, New York, NY, USA (10) Department of Respiratory Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland (11) Department of Respiratory Medicine, Beaumont Hospital, Dublin, Ireland (12) Department of Anesthesiology, Perioperative Care, and Pain Medicine, NYU Grossman School of Medicine, NY, USA (13) Gutz Analytics, Boulder CO, 80304, Rockville MD, USA (14) Department of Radiation Oncology, New York University Grossman School of Medicine, New York, New York, USA (15) Division of Precision Medicine, Department of Medicine, New York University Grossman School of Medicine, New York, NY, USA (16) Division of Hematology and Medical Oncology, Department of Medicine at NYU Grossman School of Medicine, NY, USA (17) Laura and Isaac Perlmutter Cancer Center, New York University School of Medicine, NYU Langone Health, New York, NY, USA

Immune checkpoint blockade facilitates primary tumor rejection in a cDC1-independent manner without immunological memory acquisition

Spotlight 

Arisato et al. found that the LLC-2B2 subclone of LLC was universally rejected in ICB-treated WT mice and was also rejected in 36% of ICB-treated Batf3-/- mice. In Batf3-/- mice, rejection was dependent on CD8+ T cells primed by alternative XCR1- APCs, which upregulated costimulatory CD80, CD86, and CD40 in response to soluble factors secreted by LLC-2B2 cells. However, when mice that had cleared LLC-2B2 tumors were rechallenged, all WT mice rejected tumors, while most Batf3-/- mice did not, suggesting that cDC1s were important in establishing protective immune memory. Intratumoral injection of Flt3L-DCs restored protection from rechallenge.

Contributed by Lauren Hitchings

Arisato et al. found that the LLC-2B2 subclone of LLC was universally rejected in ICB-treated WT mice and was also rejected in 36% of ICB-treated Batf3-/- mice. In Batf3-/- mice, rejection was dependent on CD8+ T cells primed by alternative XCR1- APCs, which upregulated costimulatory CD80, CD86, and CD40 in response to soluble factors secreted by LLC-2B2 cells. However, when mice that had cleared LLC-2B2 tumors were rechallenged, all WT mice rejected tumors, while most Batf3-/- mice did not, suggesting that cDC1s were important in establishing protective immune memory. Intratumoral injection of Flt3L-DCs restored protection from rechallenge.

Contributed by Lauren Hitchings

ABSTRACT: Immune checkpoint blockade (ICB) provides durable therapeutic responses across multiple cancer types. Although crosstalk between T cells and conventional type 1 dendritic cells (cDC1s) is essential, the contribution of other antigen-presenting cells (APCs) to ICB-induced tumor rejection remains unclear. To address this, we show that while the majority of wild type (WT) mice rejected an immunogenic clone of Lewis lung carcinoma (LLC) following ICB, 35.7% of Batf3–/– mice, which lack the cDC1 subset, also rejected this LLC clone. ICB induced the upregulation of costimulatory markers on XCR1– APCs in the tumors and lymph nodes of Batf3–/– mice, similar to responses observed in wild-type mice. Mechanistically, conditioned culture media from LLC, but not from ICB-resistant B16F10 melanoma cells, stimulated bone marrow-derived cDC1s and cDC2s, as evidenced by the upregulation of CD40 and CD80 expression. RNA sequencing revealed that antitumor immunity-related genes were upregulated in LLC cells compared with B16F10 cells. To determine the role of cDC1-independent long-term immune memory, we rechallenged ICB-induced tumor-free mice with LLC tumors. We found that, without supplementation of cDC1s during primary rejection, Batf3–/– mice failed to spontaneously reject the rechallenged tumors. These findings demonstrate that ICB can elicit primary antitumor T cell responses against immunogenic tumors in the absence of cDC1s, whereas cDC1s are essential for the establishment of ICB-induced long-term memory. Our study underscores the importance of clinical strategies targeting both cDC1-dependent and cDC1-independent pathways to enhance the durable efficacy of ICB.

Author Info: 1. Department of Medical Oncology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan 2. Department of Respiratory Medicine, Faculty of Medici

Author Info: 1. Department of Medical Oncology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan 2. Department of Respiratory Medicine, Faculty of Medicine, Hokkaido University, Sapporo, Japan 3. Department of Medical Oncology, Shinshu Cancer Center, Shinshu University Hospital, Matsumoto, Japan 4. Division of Molecular Psychoimmunology, Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan 5. Department of Medical Oncology, Hokkaido University Hospital, Sapporo, Japan 6. Division of Clinical Cancer Genomics, Hokkaido University Hospital, Sapporo, Japan 7. Quantum immunology Team, Institute for Quantum Life science, National Institute for Quantum and Radiological Science and Technology (QST), Chiba, Japan 8. Division of Molecular Neuroimmunology, Department of Homeostatic Regulation, National Institute for Physiological Sciences, National Institutes of Natural Sciences, Aichi, Japan 9. Institute for Vaccine Research and Development, Hokkaido University, Sapporo 001-0021, Japan

Neutralizing the IL-12/IL-23 p40 subunit prevents immune checkpoint blockade toxicity without compromising antitumor efficacy Spotlight 

Groeneveldt et al. investigated mechanisms driving early-stage immune-related adverse events (irAEs) in patients with metastatic melanoma treated with combination ICB (anti-PD-1 and anti-CTLA-4). Proteomic analysis of serum identified an early, significant increase of p40, a subunit of IL-12/I-23, prior to the onset of clinically apparent irAEs, which was not associated with ICB efficacy. In mouse models that mimic irAEs in patients, p40 neutralization prevented ICB-induced toxicity, without compromising antitumor T cell immunity, including the establishment of tumor-specific responses, suggesting distinct mechanisms that can be uncoupled.

Contributed by Katherine Turner

Groeneveldt et al. investigated mechanisms driving early-stage immune-related adverse events (irAEs) in patients with metastatic melanoma treated with combination ICB (anti-PD-1 and anti-CTLA-4). Proteomic analysis of serum identified an early, significant increase of p40, a subunit of IL-12/I-23, prior to the onset of clinically apparent irAEs, which was not associated with ICB efficacy. In mouse models that mimic irAEs in patients, p40 neutralization prevented ICB-induced toxicity, without compromising antitumor T cell immunity, including the establishment of tumor-specific responses, suggesting distinct mechanisms that can be uncoupled.

Contributed by Katherine Turner

ABSTRACT: Immune checkpoint blockade (ICB) has markedly improved overall survival in various cancers, but is associated with severe and sometimes fatal immune-related adverse events (irAEs). Current management of irAEs involves discontinuation of ICB therapy and administration of immunosuppressive drugs, such as corticosteroids, which have been associated with decreased antitumor efficacy. Although irAE development is associated with ICB response, it is currently unknown whether their underlying mechanisms are shared or distinct. To identify early and targetable drivers of irAEs, we performed proteomic analyses on the serum of patients with cancer treated with anti-PD-1 and anti-CTLA-4 combination ICB. We identified a significantly increased concentration of p40, a subunit of IL-12/IL-23, shortly after the start of ICB but before the onset of clinically apparent irAEs. Importantly, increased p40 levels were not associated with ICB efficacy. Neutralizing p40 mitigated ICB-induced toxicity in various mouse models without impairing ICB-induced antitumor efficacy. In conclusion, we demonstrated that IL-12/IL-23p40 is a key mediator of ICB-induced toxicity while being redundant for ICB antitumor efficacy. This shows that the mechanisms underlying ICB toxicity and efficacy can be uncoupled and provides a rationale for p40 blockade in clinical trials with ICB treatment to prevent irAEs in patients.

Author Info: (1) Erasmus MC Rotterdam Netherlands. ROR: https://ror.org/018906e22 (2) Erasmus MC Cancer Institute Rotterdam, South-Holland Netherlands. ROR: https://ror.org/03r4m3349 (3) Erasmu

Author Info: (1) Erasmus MC Rotterdam Netherlands. ROR: https://ror.org/018906e22 (2) Erasmus MC Cancer Institute Rotterdam, South-Holland Netherlands. ROR: https://ror.org/03r4m3349 (3) Erasmus MC Netherlands. ROR: https://ror.org/018906e22 (4) Cancer Research UK Scotland Institute United Kingdom. ROR: https://ror.org/03pv69j64 (5) Erasmus MC Cancer Institute Rotterdam Netherlands. ROR: https://ror.org/03r4m3349 (6) Erasmus MC Cancer Institute Netherlands. ROR: https://ror.org/03r4m3349 (7) Erasmus MC Rotterdam Rotterdam Netherlands. (8) Erasmus MC Cancer Institute Netherlands. ROR: https://ror.org/03r4m3349 (9) Erasmus MC Rotterdam Rotterdam Netherlands. (10) Erasmus MC Cancer Institute Rotterdam Netherlands. ROR: https://ror.org/03r4m3349 (11) Erasmus MC Cancer Institute Rotterdam Netherlands. ROR: https://ror.org/03r4m3349 (12) Erasmus MC Rotterdam Netherlands. ROR: https://ror.org/018906e22 (13) University of Warsaw Poland. ROR: https://ror.org/039bjqg32 (14) Erasmus MC Rotterdam Netherlands. ROR: https://ror.org/018906e22 (15) Erasmus MC - Sophia Children's Hospital Rotterdam, South Holland Netherlands. ROR: https://ror.org/047afsm11 (16) Erasmus MC Rotterdam Netherlands. ROR: https://ror.org/018906e22 (17) Erasmus MC Rotterdam Rotterdam Netherlands. (18) Erasmus MC Cancer Institute Rotterdam Netherlands. ROR: https://ror.org/03r4m3349 (19) Erasmus MC Cancer Institute Rotterdam Netherlands. ROR: https://ror.org/03r4m3349

Close Modal

Small change for you. Big change for us!

This Thanksgiving season, show your support for cancer research by donating your change.

In less than a minute, link your credit card with our partner RoundUp App.

Every purchase you make with that card will be rounded up and the change will be donated to ACIR.

All transactions are securely made through Stripe.